Literature DB >> 6717889

Lonidamine and radiotherapy in head and neck cancers. A pilot study.

L Magno, F Terraneo, G B Ciottoli.   

Abstract

The tolerance and antitumor activity of Lonidamine combined with radiotherapy were studied on 40 patients with head and neck cancer and compared with a historical control group. Lonidamine was well tolerated. 26 and 17 complete responses were seen in the Lonidamine-treated group and in the historical control group, respectively.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6717889     DOI： 10.1159/000225898

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  5 in total

1.  The combined use of radiation therapy and lonidamine in the treatment of brain metastases.

Authors:  L M DeAngelis; V E Currie; J H Kim; G Krol; M A O'Hehir; F M Farag; C W Young; J B Posner
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

2.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

Authors:  K W Rosbe; T W Brann; S A Holden; B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

Review 4.  Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.

Authors:  Diana Cervantes-Madrid; Yair Romero; Alfonso Dueñas-González
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

5.  Phase II study of lonidamine in metastatic breast cancer.

Authors:  P Pronzato; D Amoroso; G Bertelli; P F Conte; M P Cusimano; G B Ciottoli; M Gulisano; R Lionetto; R Rosso
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.